We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » InterMune Drug for Lung Disease Gets Panel’s Recommendation
InterMune Drug for Lung Disease Gets Panel’s Recommendation
March 12, 2010
An FDA advisory panel voted 9–3 to recommend approval of InterMune’s Esbriet to slow the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF), despite agency staff concerns about proof of efficacy.